TY  - GEN
AU  - Cohn,David E
AU  - Kim,Kenneth H
AU  - Resnick,Kimberly E
AU  - O'Malley,David M
AU  - Straughn,J Michael
TI  - At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis
SN  - 1527-7755
PY  - 2011///0527
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Bevacizumab
KW  - Carboplatin
KW  - Chemotherapy, Adjuvant
KW  - Computer Simulation
KW  - Cost-Benefit Analysis
KW  - Disease-Free Survival
KW  - Drug Costs
KW  - Female
KW  - Humans
KW  - Intestinal Perforation
KW  - economics
KW  - Models, Economic
KW  - Neoplasm Staging
KW  - Ovarian Neoplasms
KW  - drug therapy
KW  - Paclitaxel
KW  - Randomized Controlled Trials as Topic
KW  - Survival Analysis
KW  - Survival Rate
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Webcast
UR  - https://doi.org/10.1200/JCO.2010.32.1075
ER  -